HC Wainwright Predicts Genmab A/S FY2024 Earnings

Genmab A/S (NASDAQ:GMAB) – HC Wainwright issued their FY2024 earnings per share (EPS) estimates for Genmab A/S in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of $1.21 for the year. HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.28 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.35 EPS.

Other research analysts have also recently issued research reports about the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $48.00 target price (up previously from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Redburn Atlantic started coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $19.58 on Monday. The company’s fifty day moving average price is $21.09 and its two-hundred day moving average price is $23.87. Genmab A/S has a 52-week low of $19.02 and a 52-week high of $31.88. The firm has a market capitalization of $12.96 billion, a PE ratio of 19.01, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. During the same period in the prior year, the company posted $0.47 earnings per share.

Institutional Investors Weigh In On Genmab A/S

Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Genmab A/S by 229.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company’s stock valued at $1,033,000 after buying an additional 34,652 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Genmab A/S by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company’s stock worth $186,000 after acquiring an additional 827 shares in the last quarter. R Squared Ltd acquired a new position in Genmab A/S in the fourth quarter valued at about $93,000. Blue Trust Inc. increased its holdings in shares of Genmab A/S by 33.4% in the fourth quarter. Blue Trust Inc. now owns 5,757 shares of the company’s stock worth $120,000 after acquiring an additional 1,442 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Genmab A/S by 82.7% during the fourth quarter. SG Americas Securities LLC now owns 26,396 shares of the company’s stock worth $551,000 after purchasing an additional 11,949 shares during the period. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.